via Queen’s University Belfast
Scientists at Queen’s University Belfast have discovered a new molecule which has the potential to prolong the life of individuals with cystic fibrosis (CF).
The molecule represents a possible future treatment and works by altering cellular ion channels resulting in improved airway hydration and significantly increased mucus clearance.
For individuals with CF, normal airway clearance mechanisms which keep the lungs free of infection are defective. As a result, a build-up of mucus occurs and predisposes the individual to chronic bacterial infection. The ensuing cycles of chronic infection and airway inflammation cause progressive destruction of the airways, which is ultimately fatal.
The innovative approach could reduce the frequency of these infections through a novel protease inhibitor which prevents activation of the epithelial sodium channel; ENaC.
The research involved a team of scientists from Queen’s University alongside colleagues at the Royal College of Surgeons in Ireland and the University of North Carolina, and was funded by The Cystic Fibrosis Trust.
Speaking about the breakthrough, Dr Lorraine Martin from the School of Pharmacy at Queen’s University Belfast, said: “This is an important finding which could provide a novel therapeutic opportunity relevant to all individuals with CF, as the targeting of ENaC is independent of their underlying CF mutation. This strategy could prevent the significant lung damage that results from chronic cycles of infection and inflammation, with potential impact on quality of life as well as life expectancy. This is a further example of Queen’s University’s research advancing knowledge and changing lives.”
Ed Owen, Chief Executive at the Cystic Fibrosis Trust, said: “We are thrilled with these initial findings and are excited to see how the next stage of preclinical testing progresses. We are pleased to have been able to fund this world class project at its early stage and welcome the drug development programme planned over the coming years. Research is the biggest single area of investment for the Cystic Fibrosis Trust and it’s wonderful to see projects like this making such positive progress in our fight for a life unlimited.”
Currently available pharmacological alternatives are only suitable for a small subset of patients depending on the disease-causing genetic mutation.
Learn more: QUEEN’S SCIENTISTS DEVELOP NEW TREATMENT TO PROLONG LIFE OF THOSE WITH CYSTIC FIBROSIS
The Latest on: Cystic Fibrosis
via Google News
The Latest on: Cystic Fibrosis
- Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trialon August 1, 2022 at 3:43 pm
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational ...
- Using iPSCs, BU researchers create cells that represent the airways of cystic fibrosis patientson August 1, 2022 at 9:00 am
Cystic fibrosis (CF) is caused by a mutation of the CFTR gene. While there are many hundreds of known mutations, not all of them are currently treatable which means a significant number of CF patients ...
- Krystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trialon August 1, 2022 at 4:03 am
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational ...
- Former Detroit radio voice takes cystic fibrosis fight to Egypton July 28, 2022 at 7:35 pm
Laura Bonnell, long-time reporter at WWJ and WJR, brings expertise gained from her daughters' struggles to North Africa.
- Cystic Fibrosis Therapeutics Market is expected to Observe Considerable Growth Opportunities to 2030on July 27, 2022 at 10:41 pm
Cystic Fibrosis Therapeutics Market by Vendor Assessment, Technology Assessment, Partner and Customer Ecosystem, type solution, service, organization size, end-use verticals, and Region Global ...
- Study finds disparities in first evaluation of infants with cystic fibrosis from minoritized groupson July 27, 2022 at 8:04 pm
Infants from minoritized racial and ethnic backgrounds who have positive newborn screening tests for cystic fibrosis received their diagnostic follow-up for the disease later than recommended and ...
- Study finds delays in initial cystic fibrosis evaluation in infants of coloron July 27, 2022 at 4:28 pm
Cystic fibrosis is a progressive genetic disease that damages multiple organs, including the lungs and pancreas. The disease is caused by variants in the Cystic Fibrosis Transmembrane conductance ...
- Cystic Fibrosis Foundation Announces 2022 Impact Grant Recipientson July 26, 2022 at 7:00 am
The Cystic Fibrosis Foundation today announced the recipients of its seventh annual Impact Grants, a program which provides up to $10,000 in funding per year for up to two years to individuals and ...
- Children denied access to new 'life-transforming' cystic fibrosis drugon July 22, 2022 at 7:13 am
A mother of two children with cystic fibrosis has described the lack of access to a new drug as “complete discrimination”.
- Hormone infusion improves pancreatic insulin production in cystic fibrosis patients with or at risk for diabeteson July 21, 2022 at 11:12 am
Cystic fibrosis is well-known for attacking the lungs through thick blockages of mucus, but those with the condition often also develop diabetes because of the way cystic fibrosis can affect the ...
via Bing News
